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ABSTRACT
Background: There is growing evidence suggesting that interleukin-18 (IL-18) plays a 
crucial role in viral clearance and disease pathogenesis, and that single nucleotide 
polymorphisms (SNPs) within the gene may influence its production.
Objectives: To investigate the potential association of two polymorphisms ( 137G/C and   
607C/A) in the promoter region of the IL-18 gene with the risk of HBV recurrence after 
liver transplantation (LT) in Han Chinese patients.
Patients and Methods: IL-18 promoter genotyping was performed by the snapshot tech-
nique in 125 patients with HBV-related end-stage liver disease (ESLD) receiving LT in 
our center from 2004 to 2008.
Results: Among the study samples, no significant association between the IL-18 pro-
moter polymorphisms ( 137G/C and  607C/A) or haplotypes and HBV recurrence after 
LT was found.
Conclusions: The polymorphisms ( 137G/C and  607C/A) in the promoter region of the IL-
18 gene may not play a key role in HBV recurrence after LT in Han Chinese population, 
and may not be suitable predictors for HBV recurrence in clinical practice.
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1. Background
Hepatitis B virus (HBV) infection is a leading cause of 
morbidity  and  mortality,  affecting  approximately  350 
million people worldwide (1). Although the majority of 
patients recover from acute infection with HBV, a sig-
nificant proportion has an increased risk of developing 
liver cirrhosis or hepatocellular carcinoma. Currently, 
liver transplantation (LT) is regarded as the most effec-
tive therapy for patients with HBV-related end-stage liver 
disease (ESLD), which has become the leading indication 
of LT in China (2). However, recurrent HBV infection is a 
major problem in HBV-related ESLD patients undergoing 
orthotopic liver transplantation. Despite the prophylac-
tic use of hepatitis B immune globulin (HBIG) and nucle-
oside analogous lamivudine or adefovir, the incidence 
of  post-transplant  HBV  recurrence  varies  between  5% Hepat Mon. 2011;11(6):469-474
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and 10% in most centers. The HBV reinfection commonly 
leads to the rapid development of progressive liver dis-
ease resulting in a significant decrease in graft and pa-
tient survival. Improved understanding of factors that 
influence HBV recurrence after LT may help to develop 
prophylactic and therapeutic approaches to this vexing 
clinical problem. Furthermore, there is an urgent need 
to develop biomarkers that may help physicians predict 
which patients are at high risk for HBV recurrence after 
LT, enabling them to make earlier treatment.
Despite  extensive  clinical  and  basic  research  efforts, 
mechanisms  of  HBV  recurrence  after  LT  are  still  not 
clear. Factors that influence the HBV reinfection after LT 
include recipient factors (genetic factors, preoperative 
HBV replication status, extrahepatic HBV existence sta-
tus), donor factors (compromised donor liver; HLA-A, -B 
compatibilities), perioperative treatment (use of antivi-
ral agents, drug resistance, virus mutation, immunosup-
pressants protocol, blood transfusion), etc., as discussed 
in our previous review (3). Over the past few years, both 
our group and others have focused on searching for reli-
able genetic biomarkers to better distinguish subtypes 
of patients with HBV-related ESLD who have different risk 
of HBV recurrence after LT. Investigators in our group 
have established a retrospective cohort of HBV-related 
ESLD patients who underwent LT at our institution, and 
analyzed some potential biomarkers within this valu-
able  clinical  research  database.  Up  until  now,  genetic 
SNPs such as CTLA-4 (4), TLR4 (5), and FCGR3A (6) have 
been implicated in risk of HBV recurrence after LT and 
employed as a potential tool to guide specific medical 
therapy after LT in patients with HBV-related ESLD (7).
IL-18, a pro-inflammatory member of the IL-1 cytokine 
superfamily, is recognized as a key mediator of innate 
and  acquired  immune  responses  (8).  The  cytokine  IL-
18 is broadly expressed on dendritic cells, Kupffer cells, 
macrophages,  endothelial  cells,  and  vascular  smooth 
muscle cells, and is highly upregulated during inflam-
matory diseases (9). IL-18 has been implicated in hepati-
tis virus clearance or disease pathogenesis. McGuinness 
et al. reported that IL-18 levels were increased in patients 
with viral hepatitis and correlated with the extent of liv-
er injury (10). In addition, an in vivo study demonstrated 
that IL-18 could inhibit HBV replication in the livers of 
transgenic mice (11). More recently, it has been reported 
that polymorphisms at positions  607 and  137 of IL-18 
gene are associated with the IL-18 promoter transcrip-
tion activity, IL-18 expression, and disease progression 
including rheumatoid arthritis, type 1 diabetes, human 
immunodeficiency virus (HIV) infection, HCV and HBV 
clearance  (12-16).  However,  the  relationship  between 
these polymorphisms and risk of HBV recurrence after 
LT has not been reported.
2. Objectives
The aim of the present study was to investigate whether 
the IL-18 promoter polymorphisms ( 137G/C and  607C/A) 
is associated with HBV recurrence after LT in Chinese LT 
patients, and whether it would be a reference in predict-
ing HBV recurrence after LT.
3. Patients and Methods
3.1. Sample collection
A total of 125 patients with HBV-related ESLD (HBV-re-
lated fulminant hepatitis, decompensate liver cirrhosis 
or  hepatocellular  carcinoma)  who  received  LT  in  our 
center from 2004 to 2008 were enrolled in this retro-
spective study according to the same eligibility criteria 
mentioned  earlier  (5).  All  patients  were  Han  Chinese. 
Informed consent was obtained from all participants; 
the study was approved by the Ethical Review Commit-
tee of the First Affiliated Hospital, School of Medicine, 
Zhejiang University. The prophylaxis protocol, immuno-
suppression regimens and diagnosis criteria of HBV re-
currence after LT have been shown in our previous study 
(5). Patients positive for HBV-DNA would be treated with 
lamivudine  before  LT  and  with  HBIG  combined  with 
lamivudine (changed into adefovir if YMDD mutation 
was detected) for the prophylaxis of the recurrence of 
hepatitis B after LT. Patients with detectable serum HBV 
DNA at the time of operation were administered 8000 IU 
of HBIG during the anhepatic phase, in contrast to 6000 
IU in those whose serology were negative for HBV DNA 
before transplantation. A subsequent 800 IU of intra-
muscular HBIG was administered daily for the first sev-
en post-operative days, twice a week for the next three 
weeks and then 800 IU monthly thereafter to maintain 
serum  antibody  to  hepatitis  B  surface  antigen  (anti-
HBs)  concentrations.  Maintenance  immunosuppres-
sion regimens consisted of triple drugs of cyclosporine 
(CsA), rapamycin or tacrolimus, mycophenolate (MMF) 
and prednisone. The criteria of HBV recurrence after LT 
included  positive  hepatitis  B  surface  antigen  (HBsAg) 
or HBV-DNA ≥105 copies/mL on two occasions. The inci-
dence of HBV recurrence after LT was 9.6% with a mean 
recurrence time of 7.5 months by the criteria among our 
study population. A database was built for collecting the 
clinical data of patients, including their sex, age, blood 
type, MELD grade, indication for liver transplantation, 
pre-transplantation  HBeAg,  types  of  immunosuppres-
sive agents used and the HBV-related information.
3.2. Polymorphism genotyping
Genomic  DNA  was  isolated  from  EDTA-anticoagulat-
ed  whole  blood  using  the  Maxwell
®  16  (Promega  Co, 
USA). The primers were designed using Primer 3 soft-
ware  (http://frodo.wi.mit.edu/primer3/),  as  shown  in 
Table 1. SNPs at position  607C/A (rs1946518) and  137G/C 
(rs187238) in the promoter region of the IL-18 gene were 
genotyped by the technique of snapshot containing two 
steps (polymerase chain reaction and polymerase chain 
reaction), as described previously (5).Hepat Mon. 2011;11(6):469-474
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3.3. Statistical analysis
Statistical analyses were conducted using SPSS 16.0 for 
Windows®  (SPSS,  Chicago,  IL,  USA).  The  clinical  char-
acteristics, genotypes, and frequencies of alleles in pa-
tients with and without HBV recurrence were compared 
using x² test. The Hardy-Weinberg equilibrium, linkage 
disequilibrium  and  haplotype  were  analyzed  using 
Hapoview software and the website for SNPStats (http://
bioinfo.iconcologia.net/snpstats/start.htm). A p < 0.05 
was considered statistically significant.
4. Results
4.1. Patient characteristics
A total of 125 patients were enrolled in the study includ-
ing 111 men and 14 women aged between 23 and 68 years. 
The  primary  liver  diseases  in  the  present  study  were 
HBV-related decompansated liver cirrhosis (60.0%), HBV-
related hepatocellular carcinoma (32.8%) and fulminant 
hepatitis B (7.2%). To exclude the possible influence of the 
demographic factors, the potential association of  137G/C 
and  607C/A genotypes with clinical characteristics of 
patients was analyzed. There were no significant differ-
ences in gender, age, blood type, MELD grade, HBeAg sta-
tus, the use of immunosuppressive agents and primary 
liver diseases among patients with different genotypes 
in these two SNP loci (data not shown). Particularly, pre-
vious studies have indicated that immunosuppressive 
therapy  leads  to  high  HBV  replication  (17).  Therefore, 
in this study, we compared the incidence of HBV recur-
rence after LT in three groups divided according to the 
regimen for the maintenance of immunosuppression: 
CsA/prednisone/MMF  group,  tacrolimus/prednisone/
MMF  group,  and  rapamycin/prednisone/MMF  group. 
However, no significant differences in the incidence of 
HBV recurrence rate after LT were observed among the 
three studied groups (data not shown).
4.2.  IL-18  promoter  polymorphisms  (  137G/C  and   
607C/A) and HBV recurrence
The  incidence  of  HBV  recurrence  after  LT  was  9.6% 
(12/125) with a mean recurrence time of 7.5 months by 
the criteria for the diagnosis of HBV recurrence. Four 
patients were excluded from the study because the two 
SNPs were not detected. The ratio of detection was 96.8% 
(242/250).  Allele  frequencies  were  in  Hardy-Weinberg 
equilibrium in our study sample. The distribution of gen-
otype frequency and allelic frequency between patients 
with HBV recurrence and nonrecurrence was compared. 
In the loci of  137G/C, the incidence of HBV recurrence in 
recipients with C/G and G/G genotypes was 4% (1/23) and 
12% (11/96) respectively, and no patients with C/C suffered 
HBV recurrence. However, no statistical difference was 
found in either genotype or allelic frequency between 
patients  with  HBV  recurrence  and  nonrecurrence.  In 
the loci of  607C/A, the incidence of HBV recurrence in 
patients with C/C, C/A and A/A genotypes was 7.5% (3/40), 
14.8% (8/54) and 3.7% (1/27), respectively. There was also 
no significant association in either genotype or allelic 
frequency between recipients with HBV recurrence and 
nonrecurrence (Table 2). 
Different models of inheritance were analyzed to de-
tect the influence of IL-18 polymorphisms ( 137G/C and   
607C/A) on HBV recurrence after LT. However, none of 
PCR primers Sequencing primers
- 137G/C Forward:    5’CCCCTTCCTCCCAAGCTCAATA 3’
Reverse:  5’AGGTCAGTCTTTGCTATCATTCCAG 3’
5’TTTTTTTTTTTTTTTTTTTTTTTCCCC-AACTTTTACGGAAGAAAA 3’
 - 607C/A  Forward:   5’CAGGTTTTGGAAGGCACAGAGC 3’
Reverse:    5’AGGCTCTTTCCTAGGGCAATGG 3’
5’TTTTTTTTTTTTTTTTTTTTTTCTG-TTGCAGAAAGTGTAAAAATTATTA 3’
Table 1. Primers for polymerase chain reaction and sequencing of  -137G/C and  -607C/A in IL-18
Genotype HBV-recurrence [No. (%)]
P value 
Allele HBV-recurrence [No. (%)]
P value 
No   Yes No  Yes 
-137G/C 0.529 0.252
C-C 2 (1.8%) 0 (0%) C 26 (12%) 1 (4.2%)
C-G 22 (20.2%) 1 (8.3%) _ _ _
G-G 85 (80%) 11 (91.7%) G 192 (88%) 23 (95.8%)
-607C/A 0.237 0.758
C-C
C-A
A-A
37 (34%)
46 (42.2%)
26 (23.8%)
3 (25%)
8 (66.7%)
1 (8.3%)
C
_
T
120 (55%)
_
98 (45%)
14 (58.3%)
_
10 (41.7%)
Table 2. The distribution of genotypes and the allelic frequencies in the -137G/C and -607C/A of IL-18 in HBV recurrence patients and non recurrence control 
subjectsHepat Mon. 2011;11(6):469-474
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them was associated with HBV recurrence after LT (Table 
3). Linkage disequilibrium (LD) and haplotype analysis 
was performed using Haploview program. The  137G/C 
and    607C/A  polymorphisms  in  the  promoter  of  IL-18 
gene  were  poorly  linked  (r²  =  0.04).  Haplotypes  were 
also reconstructed with frequencies more than 0.1 be-
tween  137G/C and  607C/A. However, as shown in Table 
4, no significant association was found between neither 
global test nor individual haplotypes and the suscepti-
bility to HBV recurrence after LT.
5.Discussion
Our recent efforts have focused on identification of ge-
netic risk factors of recipients in an attempt to improve 
the power of predicting HBV recurrence after LT in pa-
tients with HBV-related ESLD. In the present study, we 
examined for the first time two polymorphisms ( 137G/C 
and  607C/A) in the promoter region of the IL-18 gene 
in the susceptibility to HBV recurrence after LT in Han 
Chinese patients. No significant association between the 
IL-18 promoter polymorphisms ( 137G/C and  607C/A) or 
haplotypes and HBV recurrence after LT was found. Our 
previous studies supported that cytokine gene polymor-
phisms may serve as candidate predictive factors for the 
risk of HBV recurrence after LT (18). A number of func-
tional polymorphisms within the proximal promoter of 
the IL-18 gene that may influence IL-18 activity and pro-
duction have been identified. Among these SNPs, two of 
the IL-18 promoter at positions  137 and  607 were most 
studied. Cloning and gene expression analysis demon-
strated that variation at  607C/A and  137G/C of IL-18 gene 
disrupts  cAMP-responsive  element-binding  protein 
binding site and H4TF-1 nuclear factor binding site, re-
spectively (19). Human monocytes isolated from  607A 
carriers produce more IL-18 than  607C carriers. Mono-
cytes from  137G carriers produce more IL-18 than  137C 
carriers (20). There is evidence that low production of IL-
No Yes OR a (95% CI b) P value AIC c BIC d
-137G/C Model
Codominant
G/G
G/C
C/C
0.44 82.6 91
85 (78%)
22 (20.2%)
2 (1.8%)
11 (91.7%)
1 (8.3%)
0 (0%)
1.00
0.35 (0.04–2.87)
0.00 (0.00–NA)
Dominant
G/G
G/C-C/C
85 (78%)
24 (22%)
11 (91.7%)
1 (8.3%)
1.00
0.32 (0.04–2.62)
0.22 80.7 86.3
Recessive
G/G-G/C
C/C
107 (98.2%)
2 (1.8%)
12 (100%)
0 (0%)
1.00
0.00 (0.00–NA)
0.52 81.8 87.4
Overdominant
G/G-C/C
G/C
87 (79.8%)
22 (20.2%)
11 (91.7%)
1 (8.3%)
1.00
0.36 (0.04–2.93)
0.28 81.1 86.7
Log-additive — — 0.33 (0.04–2.52) 0.21 80.6 86.2
-607C/A Model
Codominant
C/C
C/A
A/A
37 (33.9%)
46 (42.2%)
26 (23.9%)
3 (25%)
8 (66.7%)
1 (8.3%)
1.00
2.14 (0.53–8.66)
0.47 (0.05–4.82)
0.22 81.2 89.6
Dominant
C/C
C/A-A/A
37 (33.9%)
72 (66.1%)
3 (25%)
9 (75%)
1.00
1.54 (0.39–6.04)
0.52 81.8 87.4
Recessive
C/C-C/A
A/A
83 (76.2%)
26 (23.9%)
11 (91.7%)
1 (8.3%)
1.00
0.29 (0.04–2.36)
0.18 80.4 86
Overdominant
C/C-A/A
C/A
63 (57.8%)
46 (42.2%)
4 (33.3%)
8 (66.7%)
1.00
2.74 (0.78–9.65)
0.11 79.6 85.2
Log-additive — — 0.88 (0.39–2.00) 0.77 82.1 87.7
Table 3. The models inheritance for  -137G/C and  -607C/A in HBV recurrence patients and nonrecurrence control subjects
a OR: Odds ratio
b CI: Confidence Interval; 
c AIC: Akaike’s information criterion
d BIC: Bayesian information criterionHepat Mon. 2011;11(6):469-474
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18 contributes to the viral clearance. IL-18 deficiency is as-
sociated with accelerated viral clearance and enhanced 
activation of CD4+ T cells in mice with influenza A virus 
infection (11). Moreover, IL-18 has also been shown to play 
a role in organ transplantation (21). However, evidence 
on the role of IL-18 in liver transplantation is scarce, espe-
cially with regard to HBV recurrence after LT. Consider-
ing these findings, we hypothesized that the  137G/C and   
607C/A  polymorphisms  in  the  promoter  of  IL-18  gene 
might be associated with the risk of HBV recurrence af-
ter LT in recipients with HBV-related ESLD. However, no 
significant  association  between  the  two  SNPs  or  hap-
lotypes and HBV recurrence after LT was found in our 
research. To date, studies on the relationships between 
the IL-18 promoter polymorphisms ( 137G/C and  607C/A) 
and disease progression including HBV-related diseases 
are still remains controversial. Kretowski et al. reported 
an association of the IL-18  137 G > C but not the  607 C 
> A polymorphism with susceptibility to type I diabe-
tes in a Polish population (22). However, another study 
conducted in Japan revealed that patients with type I 
diabetes had a significantly increased frequency of IL-18   
607 C/A genotype compared with control subjects, but 
no significant difference in the IL-18  137 allele frequen-
cies (13). In HBV-infected patients, the  137 G and  607 C 
polymorphisms  increase  the  susceptibility  to  chronic 
progressive liver disease in Japan (23). Patients with  137 
C and  607 A may be closely linked to inhibit HBV-DNA 
replication in Chinese Han population (24). However, a 
study from Thailand showed that genotype AA in  607 
increases the risk of chronic HBV infection (25). These 
contradictory results can be explained by ethnic and ra-
cial differences, association with other genetic markers, 
and the fact that HBV-triggered cytokine network deter-
mines the outcome of HBV infection and recurrence af-
ter LT. Accordingly, further studies in other populations 
are required to validate our findings. Moreover, prophy-
laxis against HBV recurrence post-transplantation using 
lamivudine and low-dose HBIG may cause the variation 
in the results on the association between IL-18 polymor-
phisms and incidence of HBV recurrence after LT. Mean-
while, it should be noted that only two SNPs in the IL-18 
promoter region were investigated in our study; other 
SNPs in the exon, intron, 3’UTR region of IL-18 gene need 
to be examined in the future. Furthermore, the samples 
of this study was not large enough, especially, the num-
ber of patients with HBV recurrence was only 12. The real 
roles of IL-18 in HBV recurrence after LT in patients with 
HBV-related ESLD should be further investigated by large 
population-based studies. In summary, we did not find a 
significant association between the IL-18 promoter poly-
morphisms ( 137G/C and  607C/A) or haplotypes and HBV 
recurrence after LT among our study population. Other 
factors need to be investigated for their role in explain-
ing and predicting HBV recurrence after LT.
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